Southwest, Tesla, Coinbase, Apple, and More Stock Market Movers Friday

This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com. https://www.barro...

Dow ends over 700 points higher to exit bear market after Powell signals smaller interest-rate hikes ahead

U.S. stocks finished sharply higher on Wednesday, with the Dow Jones Industrial Average rising over 700 points to technically exit a bear market, after Federal Reserve Chairman Powell said the central...

An Alzheimer’s Drug’s Big Surprise: What It Means

Until this past week, there seemed to be no answers to the Alzheimer’s puzzle. The leading theory of the disease, that it was caused by a buildup of beta amyloid plaque in the brain, had been disprove...

As Time Passes, and the Weather Warms, Putin’s Power Play in Europe Loses Force

Why isn’t Putin’s move to cut off natural-gas shipments to Poland and Bulgaria causing a bigger spike in prices? Elias Stein Text size Vladimir Putin’s move to cut off natural-gas shipments to Poland ...

Biogen Stock Has Fallen 50%. Why It’s Time to Buy.

Text size Biogen’s Alzheimer’s disease treatment was once expected to be a megablockbuster. Dominick Reuter/AFP via Getty Images Shares of the biotech firm Biogen are down 50% since June 1...

Viatris stock slides 24% as analysts say sale of biosimilars to Indian partner removes key growth driver

Viatris Inc. said Monday it has agreed to combine its biosimilars portfolio with privately held Indian company Biocon Biologics Ltd. for up to $3.335 billion, as part of a broader overhaul of its busi...

Biogen’s stock falls 3.7% after announcing earnings, says it brought in $1 million in sales of Alzheimer’s drug in the fourth quarter

An earlier version of this report had the wrong consensus and revenue numbers. It has been corrected. Shares of Biogen Inc. BIIB, -1.92% were down 3.7% in premarket trading on Thursday after the compa...

Biogen’s stock tumbles after the U.S. proposes restricting access to its Alzheimer’s disease drug

Biogen Inc.’s BIIB, -8.92% stock sank 9.3% in premarket trading on Wednesday, the day after regulators proposed limiting access to the class of Alzheimer’s disease drugs that includes the company’s th...

Biogen’s Alzheimer’s Drug Aduhelm Has Another Shot at Success

Illustration by Elias Stein Text size Biogen ’s Alzheimer’s disease therapy, Aduhelm, has been a disappointment for the company since its Food and Drug Administration approval last spring, with early ...